Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Human leukocyte antigens and drug hypersensitivity.

Chung WH, Hung SI, Chen YT.

Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):317-23. Review.

PMID:
17620823
2.

Pharmacogenetics of cutaneous adverse drug reactions.

Aihara M.

J Dermatol. 2011 Mar;38(3):246-54. doi: 10.1111/j.1346-8138.2010.01196.x. Review.

PMID:
21342226
3.

Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.

Chung WH, Hung SI.

J Dermatol Sci. 2012 Jun;66(3):190-6. doi: 10.1016/j.jdermsci.2012.04.002. Epub 2012 Apr 11. Review.

PMID:
22541332
4.

T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction.

Ko TM, Chen YT.

Expert Rev Clin Immunol. 2012 Jul;8(5):467-77. doi: 10.1586/eci.12.31. Review.

PMID:
22882221
5.

Genotyping for severe drug hypersensitivity.

Karlin E, Phillips E.

Curr Allergy Asthma Rep. 2014 Mar;14(3):418. doi: 10.1007/s11882-013-0418-0. Review.

6.

HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.

Cheng CY, Su SC, Chen CH, Chen WL, Deng ST, Chung WH.

J Immunol Res. 2014;2014:565320. doi: 10.1155/2014/565320. Epub 2014 May 8. Review.

7.

Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.

Chung WH, Hung SI.

Allergol Int. 2010 Dec;59(4):325-32. doi: 10.2332/allergolint.10-RAI-0261. Epub 2010 Oct 25. Review.

8.

Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.

Kaniwa N, Saito Y.

J Hum Genet. 2013 Jun;58(6):317-26. doi: 10.1038/jhg.2013.37. Epub 2013 May 2. Review.

PMID:
23635947
9.

HLA alleles and drug hypersensitivity reactions.

Profaizer T, Eckels D.

Int J Immunogenet. 2012 Apr;39(2):99-105. doi: 10.1111/j.1744-313X.2011.01061.x. Epub 2011 Dec 3. Review.

PMID:
22136512
10.

[Exploratory study on biomarkers associated with severe cutaneous adverse reactions].

Kaniwa N.

Yakugaku Zasshi. 2011 Feb;131(2):255-61. Review. Japanese.

11.

HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.

Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A.

Clin Pharmacol Ther. 2012 Dec;92(6):757-65. doi: 10.1038/clpt.2012.189. Epub 2012 Nov 7. Review.

PMID:
23132554
12.

A recent update of pharmacogenomics in drug-induced severe skin reactions.

Wei CY, Ko TM, Shen CY, Chen YT.

Drug Metab Pharmacokinet. 2012;27(1):132-41. Epub 2011 Nov 1. Review.

13.

Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.

Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N.

BMC Med Genet. 2011 Sep 9;12:118. doi: 10.1186/1471-2350-12-118. Review.

14.

HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.

Yeo SI.

Int J Rheum Dis. 2013 Jun;16(3):254-7. doi: 10.1111/1756-185X.12050. Epub 2013 Apr 26. Review.

PMID:
23981744
15.

Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Harr T, French LE.

Orphanet J Rare Dis. 2010 Dec 16;5:39. doi: 10.1186/1750-1172-5-39. Review.

16.

Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex.

Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J.

Annu Rev Pharmacol Toxicol. 2012;52:401-31. doi: 10.1146/annurev-pharmtox-010611-134701. Epub 2011 Oct 17. Review.

PMID:
22017685
17.

Pharmacogenetics of toxic epidermal necrolysis.

Lee MT, Hung SI, Wei CY, Chen YT.

Expert Opin Pharmacother. 2010 Sep;11(13):2153-62. doi: 10.1517/14656566.2010.495120. Review.

PMID:
20536296
18.

Pharmacogenetics of drug hypersensitivity.

Phillips EJ, Mallal SA.

Pharmacogenomics. 2010 Jul;11(7):973-87. doi: 10.2217/pgs.10.77. Review.

19.

Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Pavlos R, Mallal S, Ostrov D, Pompeu Y, Phillips E.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):21-33. doi: 10.1016/j.jaip.2013.11.005. Review.

20.

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.

Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC; CPNDS clinical recommendation group.

Epilepsia. 2014 Apr;55(4):496-506. doi: 10.1111/epi.12564. Epub 2014 Mar 5. Review.

Items per page

Supplemental Content

Write to the Help Desk